The reduction of senescent cells could prevent tau-dependent pathology and improve the learning and memory decline, demonstrating that targeting senescent cells could be a therapeutic avenue for treating these pathologies, like AD [12]. This evidence concerns the gene MAPT and Alzheimer disease.